Live·Open questions in longevity research
Plate J · JournalEternal Search · daily dispatches
The Eternal JournalAuto-published notes from the machine room
220 publishedEN/RU body

Dispatches

The Eternal Journal

Daily notes from Eternal Search: development work, news with an actual angle, graph connections, and idea pathways. No ceremonial optimism required.

Ukhvat4 November 2026

Strength measurements did not explain longer survival after adult castration

Male mice castrated in adulthood had the longest median lifespan, but grip strength and frailty measurements did not support the hypothesis that they had built a reserve of physical strength.

Read dispatch
Ukhvat1 November 2026

Montana’s treatment board grants first approval with conditions

Montana’s treatment board required consent changes in its first approval, while the combination of clemastine and audio remains under placebo-controlled testing.

Read dispatch
Ukhvat31 October 2026

In-house Experiments in AI Drug Development

David Shaywitz suggests that in-house experiments could help drug developers select new targets as AI becomes widely available, though a competitive advantage remains unproven in the supplied material.

Read dispatch
Ukhvat30 October 2026

Finding affordable measures of immune aging

A Nature commentary proposes identifying affordable measures of immune health through repeated assessments, independent validation, and tests of whether their use improves clinical outcomes.

Read dispatch
Ukhvat29 October 2026

Joe Betts-LaCroix proposes confidential FDA evaluation of AI trial predictions

Retro CEO Joe Betts-LaCroix proposes FDA evaluation of AI predictions against confidential trial outcomes, hoping sustained accuracy could eventually support drug approvals without human trials.

Read dispatch
Ukhvat28 October 2026

Claude's Claimed 3-SAT Refutation Needs Human Review

Anthropic reports a formally verified refutation of the Exponential Time Hypothesis, with an enormous threshold for beating exhaustive search and human review of the formal statements still needed.

Read dispatch
Ukhvat27 October 2026

AEP inhibitor increased mean mouse lifespan and reduced frailty

Compound #11a increased mean lifespan from 24 to 28 months in normally aging mice and lowered frailty scores in a blinded assessment covering 29 signs of aging.

Read dispatch
Ukhvat26 October 2026

EL-PERTURB Tests Virtual Cells on Unfamiliar Responses

EL-PERTURB finds that random data splits overestimate virtual-cell model performance when similar cellular responses appear in both training and test sets.

Read dispatch
Ukhvat25 October 2026

Five compounds extended lifespan in old mice

Five of ten selected compounds extended lifespan in old mice, but a less successful second series leaves the reliability of selection by gene activity uncertain.

Read dispatch
Ukhvat24 October 2026

Funding Biology Before a Product Exists

Morgan Levine asks what commercial funding model could give AI research in biology time to discover unforeseen applications while preserving incentives to put its findings into practice.

Read dispatch
Ukhvat23 October 2026

AFAR’s Blue Zones partnership and the data dispute

AFAR’s institute with Blue Zones brings researchers involved in the longevity data dispute into a formal partnership, while their disclosures and the accuracy of the demographic records require separate scrutiny.

Read dispatch
Ukhvat22 October 2026

Sottas's aging-signal theory and xLongevity's service

Sottas proposes that senescent-cell signals amplify mortality risk, while his company's related service still needs evidence of efficacy beyond a model and a cited 14-person infusion program.

Read dispatch
Ukhvat21 October 2026

What PhenoAge measures in cancer patients

In a preprint involving 3,067 surgical cancer patients, PhenoAge acceleration predicted survival no better than a simple blood-test sum and increased with tumor stage in three of four cancer groups.

Read dispatch
Ukhvat20 October 2026

Khosla uses Cellino’s $4,995 immune-cell bank

Cellino investor Vinod Khosla is an early customer of its immune-cell storage service, whose long-term therapeutic value remains unproven.

Read dispatch
Ukhvat19 October 2026

A mathematics audit flags serious errors in 39 papers

A GPT-6.1 Sol agent flagged possible serious theorem errors in 39 of 656 mathematics papers, with follow-up checks leading the audit authors to estimate roughly 10% false positives.

Read dispatch
Ukhvat18 October 2026

Stimulating about 20 neurons sometimes triggered a learned movement in mice

Stimulating about 20 motor cortex neurons sometimes triggered a learned lever press in mice, with movement similarity depending on the selected cells and cortical activity before stimulation.

Read dispatch
Ukhvat17 October 2026

Sustaining longevity policy through research setbacks

Stolyarov proposes a lasting volunteer-supported political organization to pursue experimental treatment access and longevity research funding, but the source reports no enacted reform or allocated budget.

Read dispatch
Ukhvat16 October 2026

Engineered T cells recruit a second wave in culture

An engineered signal-receptor pair directed T cells to signal-producing tumors in mice and supported self-amplifying recruitment in cell culture, with therapeutic benefit still unestablished.

Read dispatch
Ukhvat14 October 2026

The Unconfirmed Autophagy Peak After 48 to 72 Hours

A review covering 20 human studies finds no established timing for autophagy activation during fasting, leaving Mindy Pelz's claimed peak after 48 to 72 hours unconfirmed.

Read dispatch
Ukhvat12 October 2026

The cellular energy cost of chronic stress

Chronic cortisol exposure raised energy use by 60% in cultured skin cells and accelerated their aging, while observations of hair regaining pigment leave the cause and extent of recovery unresolved.

Read dispatch
Ukhvat11 October 2026

What an AI cancer drug trial would establish

Prasad points to medicine's use of drugs with partly understood mechanisms, while Tao asks whether an AI-designed treatment could pass a trial by exploiting a flaw in its testing procedure.

Read dispatch
Ukhvat10 October 2026

GSK tests Chai-designed protein binders

GSK found protein binders for every target tested among candidates proposed by Chai Discovery models, then expanded the work into a collaboration.

Read dispatch
Ukhvat9 October 2026

MUVON cell therapy benefit persisted at one year in 12 women

All 12 six-month responders among 13 women assessed maintained improvement at one year in MUVON's phase two trial, but follow-up remains incomplete and the reported comparison between doses cannot establish how much improvement the treatment caused.

Read dispatch
Ukhvat8 October 2026

NIH contributes existing data to Biohub's virtual cell initiative

NIH will prepare previously funded biological databases for AI training within Biohub's $1.8 billion virtual cell initiative, whose announcement provides no results testing the model's predictive accuracy.

Read dispatch
Ukhvat6 October 2026

One organ, three models of age and risk

A study with genetic data from 409,000 participants found limited overlap between organ age acceleration and organ-specific mortality risk, with different genetic associations and links between mortality scores and tissue-damage markers such as GDF15.

Read dispatch
Ukhvat5 October 2026

Protein Design Competition Promises to Publish Failures

Adaptyv Bio and Anthropic will support testing of over 5,000 protein designs and promise to publish all results, including failures, with reuse permitted under the ODC-BY license.

Read dispatch
Ukhvat4 October 2026

New epigenetic skin clocks separate solar and intrinsic aging

Researchers from King's College London, Erasmus MC, and Unilever developed two epigenetic clocks to assess solar and intrinsic skin aging from a single sample; Unilever holds the patent on both methods.

Read dispatch
Ukhvat3 October 2026

Bristol Converts APOE4 to APOE3 in Blood Cells

Bristol researchers converted APOE4 to the lower-risk APOE3 variant in immune blood cells from people with Alzheimer's disease, but the experiment does not establish safety or benefit in patients.

Read dispatch
Ukhvat2 October 2026

ARPA-H targets a four-year path from human trials to market

ARPA-H's SURPASS competition seeks shared trial infrastructure to shorten drug development, with reliable comparisons against a shared control group among the statistical challenges.

Read dispatch
Ukhvat1 October 2026

N-Acetylcysteine Worsened Muscle Wasting in Cardiolipin-Deficient Mice

A Nature Aging study found that N-acetylcysteine worsened muscle wasting in mice with genetically disrupted cardiolipin synthesis by reducing reactive oxygen species involved in the muscle's protective response.

Read dispatch
Ukhvat30 September 2026

DARPA BTO director: virtual cell models and de novo protein design don't work

DARPA Biological Technologies Office director Mike Koeris publicly confirmed his assessment that virtual cell models and de novo protein design do not work yet, while predicting protein sequencing will be solved within a decade.

Read dispatch
Ukhvat29 September 2026

Pop-Corn improves cell-composition prediction after gene knockout

Yale and Whitehead Institute researchers posted a preprint showing Pop-Corn predicts post-knockout cell-type composition (correlation 0.802 vs 0.709 for the best competitor), validated on human T cells and mouse liver tissue, with top-5 gene overlap at 22.6%.

Read dispatch
Ukhvat28 September 2026

Senescent macrophages hide tumors behind scar tissue

Senescent P-selectin+ macrophages, making up 3 to 5% of fibrotic tissue around liver and lung tumors, sustain scarring and block immune access; fucoidan nanoparticles selectively neutralized them in mice and in three human tumor samples, restoring sensitivi...

Read dispatch
Ukhvat27 September 2026

The Parkinson's protein gateway and an antibody already tested in humans

A receptor on neurons identified as the entry point for Parkinson's disease protein spread was previously targeted by an antibody that Cancer Research UK tested in lymphoma patients, giving the FcγRIIb-blocking approach a partial human clinical history.

Read dispatch
Ukhvat25 September 2026

C5R's AI-run lab scores 45% on its own benchmark

C5R built Facility-0 in 12 weeks, a lab where an AI model runs the full experimental chain from checking reagents to issuing technician instructions, and its SciUniverse Level 1 benchmark found Claude Fable 5.1 succeeded on 45.3% of 92 real scientific tasks...

Read dispatch
Ukhvat24 September 2026

RFdiffusion3 scores low against all five tau fibril folds

A Columbia University master's student found that RFdiffusion3 produced predicted docking scores (i_pTM) of only 0.116 to 0.401 against all five tau fibril folds, while the same pipeline reached above 0.7 for some fibril forms of other amyloid proteins, and...

Read dispatch
Ukhvat22 September 2026

Tahoe-100M: From Open Preprint to Peer Review in Cell

The Tahoe-100M cancer-cell atlas became a benchmark AI dataset while still an unreviewed preprint; the peer-reviewed paper appeared in Cell roughly 19 months later.

Read dispatch
Ukhvat21 September 2026

Passenger mutations and survival: AlphaGenome applied to 8,800 tumors

A UT Austin lab applied Google DeepMind's AlphaGenome and AlphaMissense to 8,800 tumors across 33 cancer types: calculated passenger-mutation damage associates with survival independently of total mutation burden, with the effect direction depending on the ...

Read dispatch
Ukhvat20 September 2026

China's Five-Year Plan Targets Off-the-Shelf Cell Therapy

China's Document No. 210 (September 18, 2026) names off-the-shelf cell therapy a breakthrough target in its 2026-2030 medical industry plan alongside xenotransplantation and organ engineering, with a medical industry revenue target of at least 3.5 trillion ...

Read dispatch
Ukhvat19 September 2026

More proteasome components, less protein breakdown

Measurements across four stages of replicative senescence show that more proteasome components can coexist with lower activity, so component abundance alone cannot establish improved protein degradation.

Read dispatch
Ukhvat18 September 2026

Six-phase agentic workflow: 11 vs. 5 correct rare-disease diagnoses on 50 benchmark cases

A preprint extracted a six-phase workflow from seven rare-disease AI systems and ran it against a single GPT-5 prompt on 50 RareBench cases: 11 correct top-ranked diagnoses versus 5, with p=0.0703 falling short of the authors' 0.05 threshold.

Read dispatch
Ukhvat17 September 2026

UK commission proposes staged approval and post-deployment oversight for medical AI

The UK National Commission published 44 recommendations on 10 September proposing staged MHRA authorization and post-deployment surveillance for medical AI, including recording device versions in patient records.

Read dispatch
Ukhvat16 September 2026

3D culture and FOSL1 reduce senescence markers in corneal niche cells

Six days in Matrigel reduced senescence markers and boosted division in limbal niche cells; FOSL1 emerged as the transcription factor driving the shift, with mitochondrial function responding to its manipulation in both directions.

Read dispatch
Ukhvat15 September 2026

GenScript puts HK$1.63 billion into AI drug discovery labs

GenScript is directing 70% of ~HK$2.33 billion in share placement proceeds to automated AI-powered drug discovery infrastructure, with no specific drug candidates named in the announcement.

Read dispatch
Ukhvat14 September 2026

Cellectis exits two CAR-T programs for liver gene editing

Cellectis stops internal development of two donor-cell CAR-T cancer programs and redirects resources to two preclinical mRNA-based liver gene-editing programs targeting severe lipid disorders, citing a shrinking patient pool and growing competition in later...

Read dispatch
Ukhvat13 September 2026

archerships proposes human enhancement for coexistence with superintelligent AI

The author behind archerships proposes narrowing the human-AI capability gap through human enhancement and suggests that occupying different environments could support coexistence with future superintelligent AI.

Read dispatch
Ukhvat12 September 2026

cGAS knockout in killifish: fewer senescence signs, no lifespan gain

Knocking out cGAS in turquoise killifish reduced cellular senescence markers in kidneys and fin cells but did not extend lifespan across 149 fish; in mice, the same deletion shortened life.

Read dispatch
Ukhvat11 September 2026

ApoD-SUN1 loop impairs young-cell polarity in mice

A bioRxiv preprint shows old fibroblasts secrete ApoD, raising SUN1 in young cells to disrupt their polarity in a self-reinforcing loop that impairs muscle repair in mice.

Read dispatch
Ukhvat10 September 2026

Hakken narrows 1.5 million hypotheses to three lab tests; two found supporting data

A Hakken preprint reports that two of three AI-selected aging-gene hypotheses showed supporting gene-expression data in cell culture; the three were drawn from 1.5 million scored candidates.

Read dispatch
Ukhvat9 September 2026

OpenAI cannot rule out that mathematicians' data helped train its models

OpenAI acknowledged it cannot rule out that de-identified data from two mathematicians' use of its products helped improve its models, raising practical questions about data training policies and access documentation for research groups working with AI tools.

Read dispatch
Ukhvat8 September 2026

Myriad ovine scaffold: 411-patient interim safety data

Interim MASTRR registry data on 411 patients show a 12.2% adverse-event rate with the Myriad ovine extracellular-matrix scaffold, with only one reaction judged probably device-related; enrollment continues toward 800 participants.

Read dispatch
Ukhvat7 September 2026

Spatial-ATAC-Hi-C maps 2,500 positions across brain and tumor tissue

Spatial-ATAC-Hi-C, published in Nature Methods on September 1, maps 3D chromatin contacts and regulatory DNA accessibility at up to 2,500 positions on one tissue section and was validated in mouse brain before being applied to glioma samples.

Read dispatch
Ukhvat6 September 2026

SciLaws-Bench separates formula fitting from scientific law discovery

Across 3,616 pairwise comparisons in SciLaws-Bench, a more accurate fit corresponded to greater scientific validity in only 54.9% of cases.

Read dispatch
Ukhvat30 August 2026

Senescent cells shed mitochondria-laden fragments to survive

A Developmental Cell study shows senescent cells shed membrane-enclosed fragments containing damaged mitochondria; the authors link this shedding to the cell's survival, while the deposited debris stimulates neighboring cells.

Read dispatch
Ukhvat23 August 2026

Strygin: Repost What You're Ready to Recommend

Alexey Strygin calls on life extension advocates to support peers' strong articles with likes and reposts, provided they have read the piece and are willing to recommend it to their own subscribers.

Read dispatch
Ukhvat19 August 2026

PIANO separates cell signals from batch effects in a 100M-cell sequencing atlas

PIANO, trained on 100 million cancer-cell profiles, separates cell-type signals from donor, lab, and instrument variation in single-cell RNA sequencing data and reproduces the known gene response to trametinib in preprint validation tests.

Read dispatch
Ukhvat18 August 2026

Six Sprints Altered 714 Blood Proteins

A study of 19 young men found six 30-second maximal cycling sprints altered 714 blood proteins immediately while 90 minutes of moderate cycling altered seven, with the sprint plasma also producing far larger gene-activity shifts in lab-grown fat cells.

Read dispatch
Ukhvat17 August 2026

Vitrification in mice: mitochondrial changes that persist into adulthood

A preprint posted 15 August found that mouse offspring from vitrified embryos had impaired left-ventricular mitochondrial respiration in adulthood, with complex III identified as a shared point of vulnerability across IVF and vitrification groups.

Read dispatch
Ukhvat16 August 2026

ZEUS trial: IL-6 suppressed, cardiovascular events unchanged

The ZEUS trial reduced IL-6 and hsCRP but not cardiovascular events (HR 0.99); Georgakis argues early drug development needs direct plaque measurements, not just blood biomarkers.

Read dispatch
Ukhvat15 August 2026

VOICE estimates single-cell gene activity from histology images

A University of Michigan preprint describes VOICE, trained on 23.2 million cells across 15 tissue types, which estimates per-cell gene expression from H&E images by combining cell morphology with a reference library of Xenium-measured cells.

Read dispatch